Home › Companies › Maravai LifeSciences Holdings, Inc. › 2025-2026
Compiled from SEC Form N-PX filings and Maravai LifeSciences Holdings, Inc.’s Form 8-K, filed 2026-05-29 (Item 5.07 on EDGAR). Page generated 04 October 2026.
Explore Maravai LifeSciences Holdings, Inc. in the interactive database Compare manager voting policies
These tallies are Maravai LifeSciences Holdings, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-05-29 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Bernd Brust | 182,998,545 | -- | -- | 19,825,453 | 33,258,969 | Majority: yes |
| Elect Director: Gregory T. Lucier | 179,514,826 | -- | -- | 23,309,172 | 33,258,969 | Majority: yes |
| Elect Director: Luke Marker | 182,239,834 | -- | -- | 20,584,164 | 33,258,969 | Majority: yes |
| Proposal 2: Proposal to ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026. The appointment of Deloitte & Touche LLP as the Company's independent registered publi | 234,492,897 | 1,246,939 | 343,132 | -- | -- | Passed |
| Proposal 3: Proposal to approve, on a non-binding advisory basis, the compensation of the Company's named executive officers, as disclosed in the Company's proxy statement for the Annual Meeting. The Company's shareholders approved, on a non-binding and adviso | 200,054,156 | 2,457,403 | 312,439 | -- | 33,258,969 | Majority: yes |
Source: Maravai LifeSciences Holdings, Inc., Form 8-K, filed with the SEC on 2026-05-29 — read the filing on EDGAR.
Each item below shows how the 161 asset managers that disclosed a Maravai LifeSciences Holdings, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 6 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Maravai LifeSciences Holdings, Inc.’s own tally for this item (“Proposal 3: Proposal to approve, on a non-binding advisory basis, the compensation of the Company's named executive officers, as disclosed in the Company's proxy statement for the Annual Meeting. The Company's shareholde”): 200,054,156 for, 2,457,403 against, per its Form 8-K filed 2026-05-29 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.
The 160 asset managers below cast 99.3% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the company's reported shares outstanding.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| GTCR LLC | 130,834,085 | 0 | 0 | 0 | For |
| BRAIDWELL LP | 8,324,408 | 0 | 0 | 0 | For |
| 12 West Capital Management LP | 7,260,193 | 0 | 0 | 0 | For |
| Vanguard | 7,148,952 | 15,640 | 1 | 0 | For |
| BlackRock | 6,409,610 | 390,983 | 0 | 0 | For |
| MACKENZIE FINANCIAL CORP | 6,306,425 | 0 | 0 | 0 | For |
| Renaissance | 3,516,826 | 0 | 0 | 0 | For |
| T. Rowe Price | 3,083,574 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 2,823,673 | 0 | 0 | 0 | For |
| First Eagle Investment Management, LLC | 2,489,336 | 0 | 0 | 0 | For |
| Philosophy Capital Management LLC | 2,462,951 | 0 | 0 | 0 | For |
| Fidelity | 2,422,950 | 0 | 0 | 0 | For |
| FIRST EAGLE FUNDS | 2,167,166 | 0 | 0 | 0 | For |
| Charles Schwab | 1,984,927 | 0 | 0 | 0 | For |
| State Street | 1,837,662 | 0 | 0 | 0 | For |
| Royce | 1,808,448 | 0 | 0 | 0 | For |
| GENERAL AMERICAN INVESTORS CO INC | 1,716,193 | 0 | 0 | 0 | For |
| Point72 | 1,367,258 | 0 | 0 | 0 | For |
| Goldman Sachs | 1,164,258 | 0 | 0 | 0 | For |
| Northern Trust | 991,495 | 0 | 0 | 0 | For |
| First Pacific Advisors, LP | 884,883 | 0 | 0 | 0 | For |
| SYSTEMATIC FINANCIAL MANAGEMENT LP | 725,481 | 51,003 | 0 | 0 | For |
| Two Sigma | 769,420 | 0 | 0 | 0 | For |
| Citadel | 633,155 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 533,877 | 0 | 0 | 0 | For |
Showing the 25 largest of 160 asset managers. See all 160 in the interactive database.
Combines 3 wordings of this item as funds reported it.
90% Majority: yes · of votes cast
Maravai LifeSciences Holdings, Inc.’s own tally for this item (“Elect Director: Bernd Brust”): 182,998,545 for, 19,825,453 withheld, per its Form 8-K filed 2026-05-29 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.
The 49 asset managers below cast 100% of the shares they voted on this item FOR (20,186,507 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,338,210 | 0 | 39 | 0 | For |
| BlackRock | 3,764,578 | 0 | 0 | 0 | For |
| Fidelity | 2,400,756 | 0 | 0 | 0 | For |
| FIRST EAGLE FUNDS | 0 | 0 | 2,167,166 | 0 | Abstain |
| Royce | 1,808,448 | 0 | 0 | 0 | For |
| GENERAL AMERICAN INVESTORS CO INC | 1,716,193 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,014,383 | 0 | 0 | 0 | For |
| Charles Schwab | 992,147 | 0 | 0 | 0 | For |
| Goldman Sachs | 381,639 | 0 | 0 | 0 | For |
| Equitable | 253,182 | 0 | 0 | 0 | For |
| TIAA | 228,373 | 0 | 0 | 0 | For |
| Nationwide | 76,386 | 0 | 147,532 | 0 | Abstain |
| Northern Trust | 213,671 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 190,588 | 0 | 0 | 0 | For |
| Transamerica | 184,300 | 0 | 0 | 0 | For |
| Lazard | 137,703 | 0 | 0 | 0 | For |
| EA Series Trust | 90,161 | 0 | 0 | 0 | For |
| Lincoln Financial | 76,300 | 0 | 9,060 | 0 | For |
| Columbia Threadneedle | 82,898 | 0 | 0 | 0 | For |
| Global X | 74,714 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 56,575 | 0 | Abstain |
| GuideStone | 0 | 0 | 54,900 | 0 | Abstain |
| Bridge Builder Trust | 49,215 | 0 | 0 | 0 | For |
| Pacific Life | 44,759 | 0 | 0 | 0 | For |
| Invesco | 0 | 0 | 39,443 | 0 | Abstain |
Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.
Combines 3 wordings of this item as funds reported it.
89% Majority: yes · of votes cast
Maravai LifeSciences Holdings, Inc.’s own tally for this item (“Elect Director: Gregory T. Lucier”): 179,514,826 for, 23,309,172 withheld, per its Form 8-K filed 2026-05-29 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.
The 49 asset managers below cast 100% of the shares they voted on this item FOR (19,576,430 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,322,565 | 0 | 15,684 | 0 | For |
| BlackRock | 3,764,578 | 0 | 0 | 0 | For |
| Fidelity | 2,400,756 | 0 | 0 | 0 | For |
| FIRST EAGLE FUNDS | 0 | 0 | 2,167,166 | 0 | Abstain |
| Royce | 1,808,448 | 0 | 0 | 0 | For |
| GENERAL AMERICAN INVESTORS CO INC | 1,716,193 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,014,383 | 0 | 0 | 0 | For |
| Charles Schwab | 992,147 | 0 | 0 | 0 | For |
| Goldman Sachs | 381,639 | 0 | 0 | 0 | For |
| Equitable | 161,671 | 0 | 91,511 | 0 | For |
| TIAA | 0 | 0 | 228,373 | 0 | Abstain |
| Nationwide | 76,386 | 0 | 147,532 | 0 | Abstain |
| Northern Trust | 213,671 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 190,588 | 0 | 0 | 0 | For |
| Transamerica | 184,300 | 0 | 0 | 0 | For |
| Lazard | 0 | 0 | 137,703 | 0 | Abstain |
| EA Series Trust | 90,161 | 0 | 0 | 0 | For |
| Lincoln Financial | 0 | 0 | 85,360 | 0 | Abstain |
| Columbia Threadneedle | 0 | 0 | 82,898 | 0 | Abstain |
| Global X | 74,714 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 56,575 | 0 | Abstain |
| GuideStone | 0 | 0 | 54,900 | 0 | Abstain |
| Bridge Builder Trust | 49,215 | 0 | 0 | 0 | For |
| Pacific Life | 44,759 | 0 | 0 | 0 | For |
| Invesco | 39,443 | 0 | 0 | 0 | For |
Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.
Combines 3 wordings of this item as funds reported it.
90% Majority: yes · of votes cast
Maravai LifeSciences Holdings, Inc.’s own tally for this item (“Elect Director: Luke Marker”): 182,239,834 for, 20,584,164 withheld, per its Form 8-K filed 2026-05-29 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.
The 49 asset managers below cast 100% of the shares they voted on this item FOR (19,895,439 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,327,583 | 0 | 10,666 | 0 | For |
| BlackRock | 3,764,578 | 0 | 0 | 0 | For |
| Fidelity | 2,400,756 | 0 | 0 | 0 | For |
| FIRST EAGLE FUNDS | 0 | 0 | 2,167,166 | 0 | Abstain |
| Royce | 1,808,448 | 0 | 0 | 0 | For |
| GENERAL AMERICAN INVESTORS CO INC | 1,716,193 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,014,383 | 0 | 0 | 0 | For |
| Charles Schwab | 992,147 | 0 | 0 | 0 | For |
| Goldman Sachs | 381,639 | 0 | 0 | 0 | For |
| Equitable | 161,671 | 0 | 91,511 | 0 | For |
| TIAA | 0 | 0 | 228,373 | 0 | Abstain |
| Nationwide | 76,386 | 0 | 147,532 | 0 | Abstain |
| Northern Trust | 213,671 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 190,588 | 0 | 0 | 0 | For |
| Transamerica | 184,300 | 0 | 0 | 0 | For |
| Lazard | 137,703 | 0 | 0 | 0 | For |
| EA Series Trust | 90,161 | 0 | 0 | 0 | For |
| Lincoln Financial | 76,300 | 0 | 9,060 | 0 | For |
| Columbia Threadneedle | 82,898 | 0 | 0 | 0 | For |
| Global X | 74,714 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 56,575 | 0 | Abstain |
| GuideStone | 0 | 0 | 54,900 | 0 | Abstain |
| Bridge Builder Trust | 49,215 | 0 | 0 | 0 | For |
| Pacific Life | 44,759 | 0 | 0 | 0 | For |
| Invesco | 39,443 | 0 | 0 | 0 | For |
Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.
99.4% Passed · of votes cast
Maravai LifeSciences Holdings, Inc.’s own tally for this item (“Proposal 2: Proposal to ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026. The appointment of Deloitte & Touche LLP as th”): 234,492,897 for, 1,246,939 against — passed, per its Form 8-K filed 2026-05-29 (Item 5.07). Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.
The 49 asset managers below cast 100% of the shares they voted on this item FOR (22,926,426 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,338,248 | 0 | 1 | 0 | For |
| BlackRock | 3,764,578 | 0 | 0 | 0 | For |
| Fidelity | 2,400,756 | 0 | 0 | 0 | For |
| FIRST EAGLE FUNDS | 2,167,166 | 0 | 0 | 0 | For |
| Royce | 1,808,448 | 0 | 0 | 0 | For |
| GENERAL AMERICAN INVESTORS CO INC | 1,716,193 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,014,383 | 0 | 0 | 0 | For |
| Charles Schwab | 992,147 | 0 | 0 | 0 | For |
| Goldman Sachs | 381,639 | 0 | 0 | 0 | For |
| Equitable | 253,182 | 0 | 0 | 0 | For |
| TIAA | 228,373 | 0 | 0 | 0 | For |
| Nationwide | 223,918 | 0 | 0 | 0 | For |
| Northern Trust | 213,671 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 190,588 | 0 | 0 | 0 | For |
| Transamerica | 184,300 | 0 | 0 | 0 | For |
| Lazard | 137,703 | 0 | 0 | 0 | For |
| EA Series Trust | 90,161 | 0 | 0 | 0 | For |
| Lincoln Financial | 85,360 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 82,898 | 0 | 0 | 0 | For |
| Global X | 74,714 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 56,575 | 0 | 0 | 0 | For |
| GuideStone | 54,900 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 49,215 | 0 | 0 | 0 | For |
| Pacific Life | 44,759 | 0 | 0 | 0 | For |
| Invesco | 39,443 | 0 | 0 | 0 | For |
Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.
Ranked by the number of Maravai LifeSciences Holdings, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 146,426,000 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | GTCR LLC | 89.35% |
| 2 | BRAIDWELL LP | 5.69% |
| 3 | 12 West Capital Management LP | 4.96% |
| 4 | Vanguard | 4.89% |
| 5 | BlackRock | 4.64% |
| 6 | MACKENZIE FINANCIAL CORP | 4.31% |
| 7 | Renaissance | 2.40% |
| 8 | T. Rowe Price | 2.11% |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 1.93% |
| 10 | First Eagle Investment Management, LLC | 1.70% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| GTCR | 13.76% | DEF14A |
| BlackRock | 6.38% | 13F |
| West Capital Management LP | 6.09% | DEF14A |
| 12 West Capital Management LP | 4.96% | 13G |
| Vanguard Group | 4.89% | 13F |
| Renaissance Technologies | 2.91% | 13F |
| Stuart Feldman | 2.51% | 13G |
| Morgan Stanley | 2.35% | 13F |
| Point72 | 2.19% | 13F |
| State Street | 1.66% | 13F |
Percentages above are of 146,426,000 shares outstanding, as reported by Maravai LifeSciences Holdings, Inc. on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Maravai LifeSciences Holdings, Inc.’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.
At Maravai LifeSciences Holdings, Inc.'s shareholder meeting held 2026-05-26, in the 2025-2026 proxy season, 161 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 885 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF MARAVAI'S NAMED EXECUTIVE… — FOR was 99% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Maravai LifeSciences Holdings, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-05-29.
Maravai LifeSciences Holdings, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).